Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for BioCorRx (BICX) over the last 17 years, with Q3 2025 value amounting to $287688.0.

  • BioCorRx's Cash & Equivalents rose 31955333.33% to $287688.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $287688.0, marking a year-over-year increase of 31955333.33%. This contributed to the annual value of $88033.0 for FY2024, which is 3497.44% up from last year.
  • According to the latest figures from Q3 2025, BioCorRx's Cash & Equivalents is $287688.0, which was up 31955333.33% from $111872.0 recorded in Q2 2025.
  • BioCorRx's 5-year Cash & Equivalents high stood at $1.9 million for Q1 2021, and its period low was $90.0 during Q3 2024.
  • Moreover, its 5-year median value for Cash & Equivalents was $111461.0 (2022), whereas its average is $270792.8.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 9994.25% in 2024, then surged by 31955333.33% in 2025.
  • BioCorRx's Cash & Equivalents (Quarter) stood at $85838.0 in 2021, then dropped by 20.06% to $68615.0 in 2022, then fell by 4.94% to $65222.0 in 2023, then surged by 34.97% to $88033.0 in 2024, then soared by 226.8% to $287688.0 in 2025.
  • Its Cash & Equivalents was $287688.0 in Q3 2025, compared to $111872.0 in Q2 2025 and $24142.0 in Q1 2025.